ZA200300904B - Tetrazolyl-phenyl acetamide glucokinase activators. - Google Patents
Tetrazolyl-phenyl acetamide glucokinase activators. Download PDFInfo
- Publication number
- ZA200300904B ZA200300904B ZA200300904A ZA200300904A ZA200300904B ZA 200300904 B ZA200300904 B ZA 200300904B ZA 200300904 A ZA200300904 A ZA 200300904A ZA 200300904 A ZA200300904 A ZA 200300904A ZA 200300904 B ZA200300904 B ZA 200300904B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- phenyl
- tetrazol
- cyclopentyl
- thiazol
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title description 20
- 108010021582 Glucokinase Proteins 0.000 title description 20
- 239000012190 activator Substances 0.000 title description 4
- 150000003536 tetrazoles Chemical class 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- -1 perfluoro Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052757 nitrogen Chemical group 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229940080818 propionamide Drugs 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- QIMSMHHSGVQCCP-GXDHUFHOSA-N (e)-2-[3-chloro-4-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]-3-cyclohexyl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound FC(F)(F)C1=NN=NN1C1=CC=C(C(=C/C2CCCCC2)\C(=O)NC=2SC=CN=2)C=C1Cl QIMSMHHSGVQCCP-GXDHUFHOSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- ICORAYQUZBVGMS-SFQUDFHCSA-N (e)-2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cycloheptyl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCCCC2)\C(=O)NC=2SC=CN=2)C=C1Cl ICORAYQUZBVGMS-SFQUDFHCSA-N 0.000 claims description 3
- LKVCBZIKYUSOKK-LFIBNONCSA-N (e)-2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cyclohexyl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCCC2)\C(=O)NC=2SC=CN=2)C=C1Cl LKVCBZIKYUSOKK-LFIBNONCSA-N 0.000 claims description 3
- TVJZYYHQBQGIPR-XNTDXEJSSA-N (e)-3-cyclopentyl-2-[4-(5-methyltetrazol-1-yl)-3-(trifluoromethyl)phenyl]-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCC2)\C(=O)NC=2SC=CN=2)C=C1C(F)(F)F TVJZYYHQBQGIPR-XNTDXEJSSA-N 0.000 claims description 3
- HLIOSGRVEWBZSF-MHWRWJLKSA-N (e)-n-(5-bromo-1,3-thiazol-2-yl)-2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cycloheptylprop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCCCC2)\C(=O)NC=2SC(Br)=CN=2)C=C1Cl HLIOSGRVEWBZSF-MHWRWJLKSA-N 0.000 claims description 3
- NKHVFFJXXOWCEU-LICLKQGHSA-N (e)-n-(5-bromopyridin-2-yl)-3-cyclopentyl-2-[3-fluoro-4-(5-methyltetrazol-1-yl)phenyl]prop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCC2)\C(=O)NC=2N=CC(Br)=CC=2)C=C1F NKHVFFJXXOWCEU-LICLKQGHSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- VLMUMBDJCAPBLI-XNTDXEJSSA-N (e)-2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cyclopentyl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCC2)\C(=O)NC=2SC=CN=2)C=C1Cl VLMUMBDJCAPBLI-XNTDXEJSSA-N 0.000 claims description 2
- ADUWEZAFXRWDTE-LZYBPNLTSA-N (e)-4-cyclopentyl-2-[4-(5-methyltetrazol-1-yl)-3-(trifluoromethyl)phenyl]-n-(1,3-thiazol-2-yl)but-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/CC2CCCC2)\C(=O)NC=2SC=CN=2)C=C1C(F)(F)F ADUWEZAFXRWDTE-LZYBPNLTSA-N 0.000 claims description 2
- PIGACGIYJAENBN-UHFFFAOYSA-N 3-cyclopentyl-2-[4-methylsulfonyl-3-(5-methyltetrazol-1-yl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound CC1=NN=NN1C1=CC(C(CC2CCCC2)C(=O)NC=2SC=CN=2)=CC=C1S(C)(=O)=O PIGACGIYJAENBN-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- VKWFRNZZSJDCLP-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-cyclopentyl-2-[3-fluoro-4-(5-methyltetrazol-1-yl)phenyl]propanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCC2)C(=O)NC=2N=CC(Br)=CC=2)C=C1F VKWFRNZZSJDCLP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 5
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- JGXAEYXCPWTPJH-UHFFFAOYSA-N 3-cyclopentyl-2-[4-(5-methyltetrazol-1-yl)-3-(trifluoromethyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCC2)C(=O)NC=2SC=CN=2)C=C1C(F)(F)F JGXAEYXCPWTPJH-UHFFFAOYSA-N 0.000 claims 2
- RDFQPBCYHXYWEC-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-cyclopentyl-2-[4-(5-methyltetrazol-1-yl)-3-(trifluoromethyl)phenyl]propanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCC2)C(=O)NC=2N=CC(Br)=CC=2)C=C1C(F)(F)F RDFQPBCYHXYWEC-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- VCAPFFJIUXFVLZ-UHFFFAOYSA-N 2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cyclopentyl-n-(1,3-thiazol-2-yl)propanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCC2)C(=O)NC=2SC=CN=2)C=C1Cl VCAPFFJIUXFVLZ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 150000003557 thiazoles Chemical class 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 150000003222 pyridines Chemical class 0.000 description 4
- 102000005548 Hexokinase Human genes 0.000 description 3
- 108700040460 Hexokinases Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- YJDPXMKSUFTHMS-XNTDXEJSSA-N (e)-3-cyclopentyl-2-[3-fluoro-4-(5-methyltetrazol-1-yl)phenyl]-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound CC1=NN=NN1C1=CC=C(C(=C/C2CCCC2)\C(=O)NC=2SC=CN=2)C=C1F YJDPXMKSUFTHMS-XNTDXEJSSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000035180 MODY Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- LFTGTOLTMYTROZ-LFIBNONCSA-N (e)-3-cyclopentyl-2-[3-methylsulfonyl-4-(5-methyltetrazol-1-yl)phenyl]-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical group CC1=NN=NN1C1=CC=C(C(=C/C2CCCC2)\C(=O)NC=2SC=CN=2)C=C1S(C)(=O)=O LFTGTOLTMYTROZ-LFIBNONCSA-N 0.000 description 1
- FUDILUPVYTXZOP-UHFFFAOYSA-N 2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cyclohexyl-n-(1,3-thiazol-2-yl)propanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCCC2)C(=O)NC=2SC=CN=2)C=C1Cl FUDILUPVYTXZOP-UHFFFAOYSA-N 0.000 description 1
- IFFDTWTYMFUYKO-UHFFFAOYSA-N 2-[3-chloro-4-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]-3-cyclohexyl-n-(1,3-thiazol-2-yl)propanamide Chemical compound FC(F)(F)C1=NN=NN1C1=CC=C(C(CC2CCCCC2)C(=O)NC=2SC=CN=2)C=C1Cl IFFDTWTYMFUYKO-UHFFFAOYSA-N 0.000 description 1
- LPAHTBLLEJHMNM-UHFFFAOYSA-N 3-cyclopentyl-2-[3-fluoro-4-(5-methyltetrazol-1-yl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCC2)C(=O)NC=2SC=CN=2)C=C1F LPAHTBLLEJHMNM-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 101150109586 Gk gene Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- SBAGURZBQXASIS-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-2-[3-chloro-4-(5-methyltetrazol-1-yl)phenyl]-3-cyclopentylpropanamide Chemical compound CC1=NN=NN1C1=CC=C(C(CC2CCCC2)C(=O)NC=2N=CC(Br)=CC=2)C=C1Cl SBAGURZBQXASIS-UHFFFAOYSA-N 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22549400P | 2000-08-15 | 2000-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300904B true ZA200300904B (en) | 2004-04-30 |
Family
ID=22845106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300904A ZA200300904B (en) | 2000-08-15 | 2003-01-31 | Tetrazolyl-phenyl acetamide glucokinase activators. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US6369232B1 (enExample) |
| EP (1) | EP1311504B1 (enExample) |
| JP (1) | JP3961948B2 (enExample) |
| KR (1) | KR100518061B1 (enExample) |
| CN (1) | CN1209362C (enExample) |
| AR (1) | AR031718A1 (enExample) |
| AT (1) | ATE297921T1 (enExample) |
| AU (2) | AU8399801A (enExample) |
| BR (1) | BR0113312A (enExample) |
| CA (1) | CA2419416C (enExample) |
| DE (1) | DE60111540T2 (enExample) |
| DK (1) | DK1311504T3 (enExample) |
| ES (1) | ES2243541T3 (enExample) |
| MX (1) | MXPA03001275A (enExample) |
| PA (1) | PA8525201A1 (enExample) |
| PE (1) | PE20020386A1 (enExample) |
| PT (1) | PT1311504E (enExample) |
| UY (1) | UY26885A1 (enExample) |
| WO (1) | WO2002014312A1 (enExample) |
| ZA (1) | ZA200300904B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
| US7078423B2 (en) * | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| RU2005113713A (ru) * | 2002-10-03 | 2006-01-20 | Новартис АГ (CH) | Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| JP4621198B2 (ja) * | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ（シクロ）置換アミドグルコキナーゼ活性化化合物 |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| JP2007530631A (ja) | 2004-04-02 | 2007-11-01 | ノバルティス アクチエンゲゼルシャフト | チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法 |
| CA2560689C (en) | 2004-04-02 | 2011-03-01 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| TWI359149B (en) | 2005-07-11 | 2012-03-01 | Mitsubishi Tanabe Pharma Corp | An oxime derivative and preparations thereof |
| JPWO2007026761A1 (ja) | 2005-08-31 | 2009-03-12 | アステラス製薬株式会社 | チアゾール誘導体 |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| ES2381864T3 (es) * | 2005-12-15 | 2012-06-01 | Nihon Nohyaku Co., Ltd. | Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| JP5386350B2 (ja) * | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| EP2105435A4 (en) * | 2007-01-10 | 2011-06-15 | Mitsubishi Tanabe Pharma Corp | Hydrazone derivative |
| EP2116533B1 (en) | 2007-03-07 | 2013-07-10 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| WO2009047798A2 (en) * | 2007-10-08 | 2009-04-16 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| AR070107A1 (es) * | 2008-01-15 | 2010-03-17 | Lilly Co Eli | R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia |
| US8329707B2 (en) | 2008-01-18 | 2012-12-11 | Astellas Pharma Inc. | Substituted pyrazine compounds |
| HUE025224T2 (en) | 2008-04-28 | 2016-02-29 | Kyorin Seiyaku Kk | Ciklopentilakrilsav amide derivatives |
| EP3199623B1 (en) | 2010-03-31 | 2021-07-28 | The Scripps Research Institute | Reprogramming cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776917A (en) * | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
| GB8909574D0 (en) | 1989-04-26 | 1989-06-14 | Ici Plc | Chemical process |
| US5859052A (en) * | 1993-01-14 | 1999-01-12 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5461049A (en) * | 1994-05-27 | 1995-10-24 | Warner-Lambert Company | Amide tetrazole ACAT inhibitors |
| US5468867A (en) * | 1994-05-27 | 1995-11-21 | Syntex (U.S.A.) Inc. | Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid |
| AU728812B2 (en) * | 1997-01-28 | 2001-01-18 | Merck & Co., Inc. | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity |
| ES2226811T3 (es) * | 1999-03-29 | 2005-04-01 | F. Hoffmann-La Roche Ag | Activadores de glucoquinasa. |
-
2001
- 2001-08-08 US US09/924,247 patent/US6369232B1/en not_active Expired - Fee Related
- 2001-08-09 WO PCT/EP2001/009207 patent/WO2002014312A1/en not_active Ceased
- 2001-08-09 AU AU8399801A patent/AU8399801A/xx active Pending
- 2001-08-09 AU AU2001283998A patent/AU2001283998B2/en not_active Ceased
- 2001-08-09 ES ES01962926T patent/ES2243541T3/es not_active Expired - Lifetime
- 2001-08-09 CN CNB018163475A patent/CN1209362C/zh not_active Expired - Fee Related
- 2001-08-09 KR KR10-2003-7002231A patent/KR100518061B1/ko not_active Expired - Fee Related
- 2001-08-09 EP EP01962926A patent/EP1311504B1/en not_active Expired - Lifetime
- 2001-08-09 JP JP2002519452A patent/JP3961948B2/ja not_active Expired - Fee Related
- 2001-08-09 AT AT01962926T patent/ATE297921T1/de not_active IP Right Cessation
- 2001-08-09 MX MXPA03001275A patent/MXPA03001275A/es active IP Right Grant
- 2001-08-09 DE DE60111540T patent/DE60111540T2/de not_active Expired - Lifetime
- 2001-08-09 DK DK01962926T patent/DK1311504T3/da active
- 2001-08-09 BR BR0113312-8A patent/BR0113312A/pt not_active IP Right Cessation
- 2001-08-09 PT PT01962926T patent/PT1311504E/pt unknown
- 2001-08-09 CA CA002419416A patent/CA2419416C/en not_active Expired - Fee Related
- 2001-08-14 UY UY26885A patent/UY26885A1/es not_active Application Discontinuation
- 2001-08-14 AR ARP010103886A patent/AR031718A1/es active IP Right Grant
- 2001-08-14 PA PA20018525201A patent/PA8525201A1/es unknown
- 2001-08-15 PE PE2001000814A patent/PE20020386A1/es not_active Application Discontinuation
- 2001-10-11 US US09/975,713 patent/US6388088B1/en not_active Expired - Fee Related
-
2002
- 2002-01-16 US US10/050,508 patent/US6441180B1/en not_active Expired - Fee Related
-
2003
- 2003-01-31 ZA ZA200300904A patent/ZA200300904B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0113312A (pt) | 2003-07-01 |
| UY26885A1 (es) | 2002-02-28 |
| CN1466584A (zh) | 2004-01-07 |
| EP1311504A1 (en) | 2003-05-21 |
| PT1311504E (pt) | 2005-10-31 |
| JP2004506632A (ja) | 2004-03-04 |
| DE60111540D1 (de) | 2005-07-21 |
| US20020035267A1 (en) | 2002-03-21 |
| DE60111540T2 (de) | 2006-03-16 |
| JP3961948B2 (ja) | 2007-08-22 |
| MXPA03001275A (es) | 2003-06-30 |
| US6388088B1 (en) | 2002-05-14 |
| PA8525201A1 (es) | 2002-07-30 |
| DK1311504T3 (da) | 2005-10-17 |
| WO2002014312A1 (en) | 2002-02-21 |
| CN1209362C (zh) | 2005-07-06 |
| EP1311504B1 (en) | 2005-06-15 |
| CA2419416C (en) | 2009-10-13 |
| ATE297921T1 (de) | 2005-07-15 |
| ES2243541T3 (es) | 2005-12-01 |
| AU8399801A (en) | 2002-02-25 |
| CA2419416A1 (en) | 2002-02-21 |
| AU2001283998B2 (en) | 2005-10-20 |
| PE20020386A1 (es) | 2002-05-13 |
| KR100518061B1 (ko) | 2005-09-28 |
| AR031718A1 (es) | 2003-10-01 |
| US6369232B1 (en) | 2002-04-09 |
| US20020065275A1 (en) | 2002-05-30 |
| KR20030022408A (ko) | 2003-03-15 |
| US20020035266A1 (en) | 2002-03-21 |
| US6441180B1 (en) | 2002-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200300904B (en) | Tetrazolyl-phenyl acetamide glucokinase activators. | |
| ZA200303748B (en) | Fused heteroaromatic glucokinase activators. | |
| ZA200203829B (en) | Trans olefinic glucokinase activators. | |
| CA2430579A1 (en) | Isoindolin-1-one glucokinase activators | |
| EP1283830B1 (en) | Para-amine substituted phenylamide glucokinase activators | |
| KR100502033B1 (ko) | 알키닐 페닐 헤테로방향족 글루코키나제 활성제 | |
| CN101492416B (zh) | 影响葡糖激酶的化合物 | |
| DE60106599T2 (de) | Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren | |
| AU2001265914A1 (en) | Para-amine substituted phenylamide glucokinase activators | |
| AU2001283998A1 (en) | Tetrazolyl-phenyl acetamide glucokinase activators | |
| JP2004521095A5 (enExample) | ||
| US6489485B2 (en) | Para-amine substituted phenylamide glucokinase activators | |
| ZA200504474B (en) | 5-Substituted-pyrazine or pyridine glucokinase activators. | |
| ZA200304265B (en) | Isoindolin-1-one glucokinase activators. | |
| US20120142705A1 (en) | Isatin and oxindole compounds |